Literature DB >> 20437642

Pallister Killian syndrome: unusual significant postnatal overgrowth in a girl with otherwise typical presentation.

Sanda Huljev Frković1, Ivana Tonković Durisević, Ruzica Lasan Trcić, Vladimir Sarnavka, Kristina Crkvenac Gornik, Dubravka Muzinić, Ljiljana Letica, Ivo Barić, Davor Begović.   

Abstract

Pallister Killian syndrome (PKS) is a rare genetic disorder caused by tetrasomy of the short arm of chromosome 12, revealed usually in mosaic distribution of an extra i (12) (p10) chromosome in fibroblasts. The syndrome presents with a recognizable pattern of findings including pigmentary skin changes, coarse face, high forehead, sparse anterior scalp hair, hypertelorism, seizures and progressive psychomotor developmental delay. It was first described independently by Pallister in 1977 and by Killian and Teschler-Nikola in 1981. We report a case of 21 month old girl with PKS and significant overgrowth. Cytogenetic analysis was performed using the GTG banding technique. The karyotype of cultured lymphocytes was normal. The karyotype from skin fibroblasts was established as mosaic tetrasomy of 12p 47,XX,+i (12) (p10)/46,XX. The origin of the extra marker chromosome was determinated by fluorescence in situ hybridization with chromosome 12 specific DNA probes confirming that supernumerary marker is chromosome i (12p) in 68% of cells. Despite the excessive postnatal growth we found low serum growth hormone levels and reduced response to pharmacological stimulation test. This is also the first report of a postnatal patient in our country.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20437642

Source DB:  PubMed          Journal:  Coll Antropol        ISSN: 0350-6134


  1 in total

1.  Rare case of Killian-Pallister syndrome associated with idiopathic short stature detected with fluorescent in situ hybridization on buccal smear.

Authors:  Elena Sukarova-Angelovska; Mirjana Kocova; Gordana Ilieva; Natalija Angelkova; Elena Kochova
Journal:  Mol Cytogenet       Date:  2016-05-03       Impact factor: 2.009

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.